替罗非班对颈动脉支架术后肌钙蛋白变化的影响:倾向性匹配分析
本研究回顾性比较颈动脉支架术(CAS)中使用替罗非班作为胃肠外抗血小板治疗与不使用的患者,经倾向性匹配后各15例。主要终点为血清肌钙蛋白从基线至术后峰值的变化。结果显示替罗非班组肌钙蛋白峰值与基线差值及相对变化均更低,围术期无死亡、心梗、卒中或TIA发生。
要点
- 替罗非班可能减少CAS围术期心肌损伤。
- 倾向性匹配后两组各15例,肌钙蛋白差值有差异。
- 围术期及1个月随访无主要不良事件。
核心结论
- 替罗非班用于CAS可能提供围术期心肌保护并减少心肌损伤。
研究设计与样本
- 回顾性倾向性匹配分析,共纳入30例接受CAS的患者,替罗非班组与无替罗非班组各15例。
主要发现
- 基线肌钙蛋白替罗非班组为3.00(0.06; 5.20)ng/mL,无替罗非班组为4.6(0.02; 13.10)ng/mL(P=0.229)。
- 术后峰值肌钙蛋白替罗非班组为3.5(0.06; 5.50)ng/mL,无替罗非班组为6.30(0.09; 28.40)ng/mL(P=0.191)。
- 峰值与基线差值替罗非班组为0.3(0.00; 1.7)ng/mL,低于无替罗非班组的1.3(0.01; 10.00)ng/mL(P=0.044)。
- 峰值与基线相对变化替罗非班组为24.3%(0%; 44.7%),低于无替罗非班组的50%(21.3%; 80.0%)(P=0.039)。
- 住院期间及1个月随访无死亡、心肌梗死、卒中或短暂性脑缺血发作发生。
临床怎么用
- 对于接受CAS的患者,可考虑围术期使用替罗非班以减少心肌损伤,但需结合个体出血风险。
局限性
- 回顾性设计且样本量小,仅30例,结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optional periprocedural antithrombotic management for carotid artery stenting (CAS) is still debated. METHODS: We aimed to compare the procedural and 1-month outlook of patients undergoing CAS with tirofiban as parenteral antiplatelet therapy. We retrospectively compared patients receiving tirofiban during CAS versus those undergoing CAS without tirofiban, using propensity score matching. Ancillary antithrombotic therapy included in all patients aspirin, clopidogrel, and unfractioned heparin. The primary outcome was the change in serum troponin from baseline to postprocedural peak levels. A total of 30 patients undergoing CAS were included, 15 receiving tirofiban on top of heparin and dual oral antiplatelet therapy (DAPT) and 15 receiving only heparin and DAPT. Bail-out use of tirofiban was an exclusion criterion. RESULTS: Baseline troponin was 3.00 (0.06; 5.20) ng/mL in the tirofiban group vs. 4.6 (0.02; 13.10) ng/mL in the no-tirofiban group (P = 0.229), and postprocedural peak 3.5 (0.06; 5.50) ng/mL vs. 6.30 (0.09; 28.40) ng/mL (P = 0.191). Peak-baseline difference in troponin was lower in the tirofiban group than in the no-tirofiban group: 0.3 (0.00; 1.7) ng/mL vs. 1.3 (0.01; 10.00) ng/mL (P = 0.044); the relative peak-baseline change in troponin was analogously different: 24.3% (0%; 44.7%) vs. 50% (21.3%; 80.0%) (P = 0.039). No case of death, myocardial infarction, stroke, or transient ischemic attack occurred during in-hospital stay or at 1-month follow-up. CONCLUSIONS: Tirofiban during CAS might provide periprocedural myocardial protection and reduce myocardial injury as determined by serial troponin measurements.
引用
- Corcione N, Pepe M, Ferraro P, et al. Impact of Tirofiban on Serum Troponin Changes in Patients Undergoing Carotid Artery Stenting: A Propensity Matched Analysis. Ann Vasc Surg. 2019. PMID: 31629846. doi:10.1016/j.avsg.2019.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。